Ameriprise’s MaxCyte MXCT Stock Holding History

Ameriprise’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97.8K	Sell	79,472 -64,615	-45%	-$64.4K	﹤0.01%	4024
2026 Q1	$101K	Sell	144,087 -29,886	-17%	-$27.9K	﹤0.01%	3958
2025 Q4	$270K	Buy	+173,973	New	+$278K	﹤0.01%	3835
2024 Q4	–	Sell	-1,116,300	Closed	-$4.34M	–	4133
2024 Q3	$4.34M	Sell	1,116,300 -17,075	-2%	-$71.9K	﹤0.01%	2471
2024 Q2	$4.44M	Sell	1,133,375 -10,162	-0.9%	-$43.7K	﹤0.01%	2392
2024 Q1	$4.79M	Sell	1,143,537 -305,370	-21%	-$1.43M	﹤0.01%	2406
2023 Q4	$6.81M	Buy	1,448,907 +139,629	+11%	+$544K	﹤0.01%	2106
2023 Q3	$4.08M	Sell	1,309,278 -10,461	-0.8%	-$42.1K	﹤0.01%	2441
2023 Q2	$6.06M	Sell	1,319,739 -9,826	-0.7%	-$45.2K	﹤0.01%	2193
2023 Q1	$6.58M	Buy	+1,329,565	New	+$6.55M	﹤0.01%	2120

Other funds holding MXCT

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $128M AUM

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Ameriprise's MXCT Position: Q2 2026 in Review

Ameriprise reduced its MaxCyte (MXCT) stake by 45% in Q2 2026, selling an estimated $64.4K and leaving 79,472 shares worth $97.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4024.

Ameriprise first reported a position in MXCT in Q1 2023 and has held it in 10 quarters since. The position peaked at $6.81M in Q4 2023. 122 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

Ameriprise held 79,472 shares of MaxCyte worth $97.8K as of Q2 2026.
Ameriprise sold 64,615 MaxCyte shares in Q2 2026, an estimated $64.4K.
MaxCyte made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #4024 holding.
Ameriprise first reported a position in MaxCyte in Q1 2023 and has held it in 10 quarters since.
Ameriprise's MaxCyte position peaked at $6.81M in Q4 2023.
122 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.